Novel PLEC-EML4-ALK Double Fusion Underlying Crizotinib Resistance in a Metastatic Inflammatory Myofibroblastic Tumor: A Case Report

Novel PLEC-EML4-ALK Double Fusion Underlying Crizotinib Resistance in a Metastatic Inflammatory Myofibroblastic Tumor: A Case Report

ALK fusions are frequent oncogenic drivers in inflammatory myofibroblastic tumors. Treatment with crizotinib is effective in fusion-positive patients; however, acquired resistance remains a challenge. Here, we present a case of EML4-ALK-positive metastatic inflammatory myofibroblastic tumor that ini...

Full description

Saved in:
Bibliographic Details
Main Authors: Alessandra Maleddu, MD, Trista K. Hinz, MS, Margaret A. Black, MD, Dara L. Aisner, MD, PhD, Carrie B. Marshall, MD, Anthony D. Elias, MD, Breelyn A. Wilky, MD, Lynn E. Heasley, PhD, Kurtis D. Davies, PhD
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:JTO Clinical and Research Reports
Subjects:
Case report
ALK fusion
Crizotinib
Inflammatory myofibroblastic tumor
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364325000074
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2666364325000074

Similar Items